



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 gp120 Monoclonal (5F7)

Catalog Number: 2533

Lot Number: 160242

Release Category: D

Provided: 1 mL of culture supernatant

Description: A monoclonal antibody to HIV-1 gp120, specifically the V3 loop (epitope: RIQRGPGRAFVTIGK)

Host: Mouse

Titer: The user should determine the optimal concentration for any application.

Special Characteristics: This antibody was produced in cell culture. It originates from a hybridoma. The hybridoma was created by immunizing Balb/c mice with HIV-1 gp120 (aa 308-322) fused to HBcAG particles. The resulting splenocytes were fused to Ag8653 myeloma cells. 5F7 recognizes HIV-1 LAI gp160 and the V3 peptide RIQRGPGRAFVTIGK (aa 308-322) in ELISA. The antibody inhibits syncytium formation, RT activity, and p24 production *in vitro* (partial inhibition and retardation over 20 days). Please see the [LANL HIV Immunology Database](#) for more information. Applications: ELISA, Western Blot, IFA

Recommended Storage: Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Albrecht von Brunn (Courtesy of CFAR, NIBSC)

Isotype: IgG₁

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

von Brunn, A., Brand, M., Reichhuber, C., Morys-Wortmann, C., Deinhardt, F., & Schödel, F. (1993). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. *Vaccine*, 11(8), 817-824. [PUBMED](#)

von Brunn A., Reichhuber C., Brand M., Bechowsky B., Gürtler L., Eberle J., Kleinschmidt A., Erfle V., Schödel F. (1993). The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. *Vaccines* 93, Cold Spring Harbor Press; Cold Spring Harbor, New York, 159-165. [ARTICLE](#)

NOTE:

Publications should acknowledge the contributor and the Centre for AIDS Reagents. Acknowledgments should read: "The Anti-HIV-1 gp120 Monoclonal (5F7), NIH-ARP# 2533 (CFAR# 3013) was obtained from the Centre for AIDS Reagents, NIBSC, UK, supported by EURIPRED (EC FP7 INFRASTRUCTURES-2012 - INFRA-2012-1.1.5.: Grant Number 31266). www.euripred.eu/ Also include the references cited above in any publications.

Last Updated

June 25, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.